VALIENT: Phase 1 Clinical Trial of VorAsidenib in Combination With Lomustine In Patients With rEcurrent IDH-mutaNT Glioma Harboring IDH1 and/or IDH2 Mutations
This study is testing a new combination of two medicines, vorasidenib and lomustine, to treat brain tumors that have come back. The main goal is to find the right dose that is safe for patients while working to slow down tumor growth caused by specific genetic mutations.
This study is for adults 18 and older who have a specific type of brain tumor (glioma) with IDH1 or IDH2 genetic mutations that has returned. You must be able to perform daily activities and meet specific health criteria, such as having recovered from recent cancer treatments.
Participants will take the combination of medications and be closely monitored by the research team to ensure safety. You will need to attend regular clinic appointments and provide blood samples to help the doctors see how your body reacts to the treatment.
The study is located in Pittsburgh, Pennsylvania, and it is currently not yet recruiting participants. This means the study team is preparing to open for enrollment soon.
- 1The study combines a new targeted therapy with traditional chemotherapy to fight recurrent brain tumors.
- 2Your safety is the top priority as doctors work to determine the best and most tolerable dosage.
- 3You will receive dedicated care and monitoring from a specialized team throughout the duration of the trial.
No related links yet
Seen this study covered in the news, or found a page that explains it well? Send it over and we'll review it.
Suggest a linkThis summary was generated using AI and may not capture all details. Always consult with a healthcare professional for medical advice.